Latest Articles about PTX

Pernix Reports Loss in 1Q - Analyst Blog

Zacks Equity Research — Mon, 13 May 2013 23:16:15 Z

Pernix Therapeutics Holdings, Inc's ( PTX ) first quarter 2013 adjusted loss (including stock-based compensation expense) of 6 cents per share, compared unfavorably to the Zacks Consensus

Pernix Reports Loss in 4Q - Analyst Blog

Zacks Equity Research — Thu, 21 Mar 2013 22:33:16 Z

Pernix Therapeutics Holdings, Inc ( PTX ) posted a loss of 2 cents per share in the fourth quarter of 2012 compared to earnings of 15 cents per share in the year-ago quarter. The

Pre-Market Earnings Report for March 18, 2013 : KIOR, IMOS, NMRX, TA, HWCC, INSM, AMRC, PTX, STRL, HZNP, UTSI, DEXO

NASDAQ.com News — Sat, 16 Mar 2013 00:00:04 Z

The following companies are expected to report earnings prior to market open on 03/18/2013. Visit our Earnings Calendar for a full list of expected earnings releases. KiOR, Inc. ( KIOR )

Pernix Completes Somaxon Buy - Analyst Blog

Zacks Equity Research — Tue, 12 Mar 2013 02:29:33 Z

Pernix Therapeutics Holdings, Inc . ( PTX ) recently completed its previously announced acquisition of Somaxon Pharmaceuticals for $25 million. The acquisition was announced on Dec 11,

Actavis in Patent Challenge - Analyst Blog

Zacks Equity Research — Tue, 12 Mar 2013 01:12:02 Z

Actavis, Inc. ( ACT ) announced that it has amended its abbreviated new drug application (ANDA) for its generic version of Novartis' ( NVS ) Exelon Patch (rivastigmine transdermal

Setback for Impax, Shares Plunge - Analyst Blog

Zacks Equity Research — Thu, 07 Mar 2013 03:55:01 Z

Impax Laboratories, Inc. ( IPXL ) recently announced that the US Food and Drug Administration (FDA) completed its re-inspection of the company's manufacturing facility at

Good News for Pernix Therapeutics - Analyst Blog

Zacks Equity Research — Wed, 06 Mar 2013 02:55:06 Z

Pernix Therapeutics Holdings, Inc ( PTX ) recently announced that its subsidiary, Hawthorn Pharmaceuticals, Inc., has received approval from the US Food and Drug Administration (FDA) for

Teva Enrolls First Patient in Study - Analyst Blog

Zacks Equity Research — Wed, 13 Feb 2013 03:10:01 Z

Teva Pharmaceutical Industries Ltd. ( TEVA ) recently announced that it has enrolled the first patient in the phase IV MODERATO ( M ulticenter, Rand o mized, D ouble-Blind,

Perrigo in Expansion Mode - Analyst Blog

Zacks Equity Research — Wed, 13 Feb 2013 02:15:01 Z

Perrigo Company ( PRGO ) recently announced that it is set to acquire a UK-based privately held pharmaceutical company, Rosemont Pharmaceuticals Ltd. and has entered into a definitive

Lannett Beats, Ups Guidance - Analyst Blog

Zacks Equity Research — Tue, 12 Feb 2013 00:24:01 Z

Lannett Company, Inc. ( LCI ) reported second quarter fiscal 2013 earnings of 10 cents per share, above the Zacks Consensus Estimate of a loss of 3 cents and the year-ago earnings of 2

Oxtellar XR Launched by Supernus - Analyst Blog

Zacks Equity Research — Wed, 06 Feb 2013 04:10:01 Z

Supernus Pharmaceuticals, Inc. ( SUPN ) recently announced the launch of its antiepileptic drug, Oxtellar XR, in the US. Oxtellar XR was approved by the US Food and Drug Administration

Teva Ends CureTech Collaboration - Analyst Blog

Zacks Equity Research — Mon, 04 Feb 2013 23:40:01 Z

Teva Pharmaceutical Industries Ltd. ( TEVA ) recently terminated its collaboration with CureTech Ltd. for the development of CT-011. The companies had signed the collaboration agreements in

Actavis Provides 2013 Guidance - Analyst Blog

Zacks Equity Research — Fri, 01 Feb 2013 02:40:01 Z

Actavis, Inc. ( ACT ), formerly known as Watson Pharmaceuticals, Inc., recently provided an update on its 2012 performance, 2013 outlook and prospects. The company said that it expects

PTX Reduces Sales Force, CFO Quits - Analyst Blog

Zacks Equity Research — Tue, 29 Jan 2013 03:18:47 Z

Pernix Therapeutics Holdings, Inc. ( PTX ) recently announced the integration of Hawthorn Pharmaceutical's sales forces with its own. Moreover, the company restructured the combined sales

Generic Launch at Dr. Reddy's - Analyst Blog

Zacks Equity Research — Tue, 29 Jan 2013 02:30:01 Z

Dr. Reddy's Laboratories Ltd. ( RDY ) recently announced that it has launched its generic version of Merck & Co., Inc. 's ( MRK ) Clarinex Reditabs (desloratadine 2.5 mg and 5